IDYA
$34.27
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Recent News
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company plans to evaluate the safety, tolerability, […]
Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone
IDEAYA Biosciences (IDYA) is in focus after dosing the first patient with IDE034 in a Phase 1 trial, a key step for this bispecific TOP1 antibody drug conjugate and its partnership with Biocytogen. See our latest analysis for IDEAYA Biosciences. IDEAYA's recent IDE034 dosing news sits alongside a run of company updates, including a new Chief Development Officer, a shelf registration filing and full year 2025 results. The latest share price of $32.20 comes after a 1 year total shareholder...
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch
IDEAYA Biosciences (NASDAQ:IDYA) outlined upcoming clinical milestones for its precision oncology pipeline, emphasizing an imminent top-line readout in first-line metastatic uveal melanoma (MUM), continued advancement of its antibody-drug conjugate (ADC) portfolio, and the early clinical launch of a
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit
IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology Leadership Summit, led by an end-of-March top-line readout for the company’s randomized trial of darovasertib plus crizotinib in metastatic uveal melanoma (MUM). Management also